Home | About PM | Editorial board | Search | Ahead of print | Current Issue | Archives | Instructions | Subscribe | Advertise | Contact us |  Login 
Pharmacognosy Magazine
Search Article 
Advanced search 
Year : 2021  |  Volume : 17  |  Issue : 73  |  Page : 193-199

Eriocitrin alleviates the arterial occlusion-mediated cerebral ischemic-reperfusion injury through the modulation of apoptotic proteins and immune markers in mice

1 Department of Intensive Care Unit, Affiliated Hospital of Beihua University, Jilin city, Jilin Province, 132011, P.R. China
2 Department of Rehabilitation, Shanghai Putuo People's Hospital, Putuo People's Hospital Affiliated to Tongji University, Department of Rehabilitation, Shanghai Putuo People's Hospital, Shanghai, 200060, P.R. China
3 Department of Pharmacy, Zhangzhou Hospital Affiliated to Fujian Medical University, Zhengzhou, Fujian, 363000, P.R. China
4 Department of Rehabilitation Medicine, The 910th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army, Quanzhou, 362000, P.R. China

Correspondence Address:
Weixiang Xue
Department of Rehabilitation Medicine, The 910th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army, Quanzhou 362000
P.R. China
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/pm.pm_577_19

Rights and Permissions

Background: Stroke is ranked on top of the persistent ailments associated with the brain. The incidence of ischemic stroke is rapidly rising along with intensified mortality as well as permanent disability conditions. However, tissue plasminogen activator (tissue-type plasminogen activator) is the only FDA-approved treatment for the treatment of stroke with decreased success rate. Eriocitrin, a flavonoid compound of Citrus limon with incredible therapeutic values, was active in the current investigation to explore the neuroprotective capability in arterial occlusion-provoked cerebral ischemic reperfusion injury (CIRI) in mouse replica. Materials and Methods: The neurological defects were considered through the standard scoring method and the expression status of apoptotic proteins, i.e., nuclear factor kappa B (NF-ƙB), caspase-3, and caspase-9, was examined via western blotting test. The expression of neuronal nitric oxide synthase (nNOS) was scrutinized through real-time polymerase chain reaction and standard ELISA kits were employed to examine the status of the proinflammatory markers. Results: The arterial occlusion provoked cerebral ischemic animals displayed the severely elevated status of inflammatory markers namely interleukin-6 (IL-6), IL-1β and tumor necrosis factor α, and the expression statuses of apoptotic proteins, as well as nNOS, were also uplifted while comparing to the sham subjected animals. Amazingly, eriocitrin (100 mg/kg) treatment revealed the declined inflammatory markers level, besides, the expression patterns of apoptotic proteins and nNOS were also reduced noticeably in the cerebral ischemic-reperfusion-operated animals. Conclusion: The novel findings of this investigation were demonstrated that the Eriocitrin delivered an astounding neuroprotection in the arterial occlusion-mediated CIRI in mouse replica, which possibly a promising neuroprotectant in cerebral ischemia.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded204    
    Comments [Add]    
    Cited by others 2    

Recommend this journal